Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Particularly salient are the following: (1) gene amplification is related to increasing grade of human glioma malignancy and occurs in approximately 40% of the most common and most malignant variety of glioma, glioblastoma multiforme (GBM), (2) by far the most commonly amplified gene in glioblastomas is the epidermal growth factor receptor (EGFR) gene, which is amplified in about one third of GBMs, (3) a small percentage of GBMs amplify N-myc or the novel sequence gli, (4) the EGFR gene is rearranged in at least half of gliomas in which it is amplified, and (5) EGFR gene rearrangement results in external domain deletions that yield truncated EGF receptors.
|
1374522 |
1992 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.
|
1693434 |
1990 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have compared the T-CAR1 cells with the human glioblastoma cell line T-MG1, which has 135,000 EGF-receptors and is growth stimulated by EGF.
|
1701094 |
1990 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Two transplantable cell lines of human glioblastoma multiforme GL-3 and GL-5 carried an amplification and overexpression of structurally altered epidermal growth factor (EGF) receptor gene: the 140 kilodalton EGF receptors in these cases exhibited a constitutively expressed tyrosine kinase activity without the ligand.
|
2168866 |
1990 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The gene encoding the receptor for epidermal growth factor was amplified two- to fivefold in the human glioblastoma cell line SF268.
|
3263568 |
1988 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In view of the similarity to the activated viral and cellular erbB genes in the avian system, these mutated and overexpressed EGF receptors might play a role in the onset or development of human glioblastoma cells.
|
3380099 |
1988 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In total, these results indicate that the aberrant EGF receptor synthesized in glioblastomas, and which lacks a portion of the extracellular domain necessary for ligand binding, is an activated tyrosine kinase.
|
8036013 |
1994 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, immunoreactivity for the EGF receptor prevailed in primary glioblastomas (63%) but was rare in secondary glioblastomas (10%).
|
8864278 |
1996 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, glioblastomas may emerge from the microenvironmental outgrowth of more malignant clones in a complex vicious cycle that involves necrosis, hypoxia, growth factor release, angiogenesis and clonal selection; growth signals mediated by activation of epidermal growth factor receptors may precipitate glioblastomas.
|
9161727 |
1997 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.
|
9334810 |
1997 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Primary (de novo) glioblastomas are characterized by amplification/overexpression of the EGF receptor (EGFR) and, less frequently, of the MDM2 gene.
|
9370234 |
1997 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we report the development and selection for a rearranged amplified EGF receptor, which lacks cytoplasmic amino acid sequences in a human glioblastoma xenograft.
|
10411339 |
1999 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Kinase-deficient erbB proteins reduced epidermal growth factor (EGF)-induced tyrosine phosphorylation of endogenous Shc proteins and also reduced immediate and sustained EGF-induced ERK MAPK activities in human glioblastoma cells, although basal ERK MAPK activities were unaffected.
|
10541432 |
1999 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor.
|
10576656 |
1999 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Primary (de novo) glioblastomas develop in older patients and are characterized by epidermal growth factor (EGF) receptor amplification/overexpression, p16 deletion, and PTEN mutations, whereas secondary glioblastomas that progressed from low-grade or anaplastic astrocytoma develop in younger patients and frequently contain p53 mutations.
|
10666371 |
2000 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Retroviral vectors made with the fusion protein were able to bind peptide antigen and EGFRvIII expressed on the surface of human glioblastoma cells.
|
10725459 |
2000 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A mutant epidermal growth factor (EGF) receptor missing 267 amino acids from the exoplasmic domain is common in human glioblastomas.
|
11087732 |
2001 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
|
11454673 |
2001 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells.
|
11515790 |
2001 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The atypical protein kinase C inhibitor induced rapid apoptosis in glioblastoma cells expressing EGFRvIII and killed these cells with an IC50 of 16 microM.
|
12014630 |
2002 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells.
|
12532415 |
2003 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
DAB(389)EGF may have potential for intracranial therapy of EGFR-positive glioblastomas.
|
12702570 |
2003 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
|
14624623 |
2004 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that a single nucleotide polymorphism in EGF may play a role in the formation of glioblastomas, is a useful and powerful prognostic marker for these patients, and may be a target for tumor therapy.
|
14973082 |
2004 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.
|
15700833 |
2004 |